These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30198315)

  • 1. Comparative Pharmacokinetic Profile of 3 Batches of Ovine Low-Molecular-Weight Heparin and 1 Batch of Branded Enoxaparin.
    Jeske W; Kouta A; Duff R; Rangnekar V; Niverthi M; Hoppensteadt D; Fareed J; Yao Y
    Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):150S-156S. PubMed ID: 30198315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and evaluation a new generation of low molecular weight heparin.
    Zhao D; Sang Q; Cui H
    Biomed Pharmacother; 2016 Apr; 79():194-200. PubMed ID: 27044828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version.
    Qneibi D; Ramacciotti E; Macedo AS; Caffaro RA; Agati LB; Siddiqui F; Kouta A; Hoppensteadt D; Fareed J; Carter CA
    Clin Appl Thromb Hemost; 2020; 26():1076029620960820. PubMed ID: 32996340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
    Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
    Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV; Béguin S; Caplain H; Hemker HC
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the antithrombotic fingerprint of the branded and copies of the low-molecular-weight enoxaparin using thrombin generation assay.
    Gerotziafas GT; Rouseau A; Mbemba E; Khartechi A; Van Dreden P; Walenga J; Fareed J; Elalamy I
    Clin Appl Thromb Hemost; 2015 Nov; 21(8):697-704. PubMed ID: 26023170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the pharmacodynamic behavior of branded and biosimilar enoxaparin in primates.
    Jeske W; Litinas E; Khan H; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2012 Jun; 18(3):294-8. PubMed ID: 22275388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates.
    Jeske W; Fareed J
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():41-7. PubMed ID: 15085465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
    Hoppensteadt DA; Jeske W; Fareed J; Bermes EW
    Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S57-64. PubMed ID: 7647223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative studies on branded enoxaparin and a US generic version of enoxaparin.
    Walenga JM; Jeske WP; Hoppensteadt D; Cunanan J; Khan H; Escalante V; Fareed J; Bakhos M
    Clin Appl Thromb Hemost; 2013 Jun; 19(3):261-7. PubMed ID: 23091283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin.
    Chen J; Yu Y; Fareed J; Hoppensteadt D; Jeske W; Kouta A; Jin C; Jin Y; Yao Y; Xia K; Zhang F; Chen S; Ye X; Linhardt RJ
    Clin Appl Thromb Hemost; 2019; 25():1076029619840701. PubMed ID: 30987427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates.
    Kouta A; Hoppensteadt D; Bontekoe E; Jeske W; Duff R; Cera L; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029620951851. PubMed ID: 33034200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
    Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
    Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Lim W; Dentali F; Eikelboom JW; Crowther MA
    Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
    Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
    PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity.
    Morris TA; Jacobson A; Marsh JJ; Lane JR
    Thromb Res; 2005; 115(1-2):45-51. PubMed ID: 15567452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
    Spencer FA; Ball SP; Zhang Q; Liu L; Benoit S; Becker RC
    J Thromb Thrombolysis; 2000 Apr; 9(3):223-8. PubMed ID: 10728020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.